Continual reassessment methods in phase I trials of the combination of twodrugs in oncology

Most phase I trials in oncology use standard methods for treating successiv e groups of patients with increasing doses in order to determine the maximu m tolerated dose (MTD). These methods have been criticized because they tre at many patients at suboptimal dose levels, and do not provide an accurate estimation of the best dose level. Continual reassessment methods for the s tudy of toxicity in single agent phase I trials have recently been advocate d since they present many advantages over traditional methods. Although the advantages of these methods are recognized by most clinical investigators, their use is not widespread and their advantages have not yet been univers ally accepted. A maximum likelihood continual reassessment method was condu cted retrospectively and compared to the originally planned standard method in a two drug combination phase I trial in order to study its applicabilit y in this setting. Calculations from the binomial distributions and simulat ions were used for identifying the MTD, for the proportion of patients trea ted at the MTD or at one dose level just below, and for the proportion of p atients treated at doses above the MTD. If the new method had been applied in this study, the MTD would have been reached much earlier, since, most of the time, higher dose levels were recommended. This result shows the feasi bility of the new method in a two-drug setting and its use should be encour aged since fewer patients are treated at suboptimal dose levels or at dose levels above the MTD. Copyright (C) 1999 John Wiley & Sons Ltd.